- ISIN
- US87911K1007
- CUSIP
- 87911K100
- Sector
- Financial Services
- Industry
- Asset Management
- IPO Date
- May 4, 1992
Highlights
- Market Cap
- $557.68M
- Enterprise Value
- $556.83M
- EPS (TTM)
- $6.27
- PE Ratio
- 2.92
- PEG Ratio
- 0.07
- Total Revenue (TTM)
- $79.82M
- Gross Profit (TTM)
- $56.06M
- EBITDA (TTM)
- $150.93M
- Year Range
- $12.67 - $18.49
- ROA (TTM)
- 33.02%
- ROE (TTM)
- 33.16%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
HQL Performance Chart
Tekla Life Sciences Investors (HQL) is up 16.6% since the beginning of the year. At $18 per share, HQL is trading just below its 52-week high of $18. Investors who bought $1,000 worth of HQL shares 5 years ago would now be looking at an investment worth $1,526.
Loading charts...
Returns By Period
Tekla Life Sciences Investors (HQL) has returned 16.62% so far this year and 65.26% over the past 12 months. Over the last ten years, HQL has returned 10.81% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Tekla Life Sciences Investors
- 1D
- 2.12%
- 1M
- 6.69%
- YTD
- 16.62%
- 6M
- 14.44%
- 1Y
- 65.26%
- 3Y*
- 24.50%
- 5Y*
- 8.82%
- 10Y*
- 10.81%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
HQL Monthly Returns History
Based on dividend-adjusted daily data since May 4, 1992, HQL's average daily return is +0.05%, while the average monthly return is +0.99%. At this rate, an investment would double in approximately 5.9 years.
Historically, 55% of months were positive and 45% were negative. The best month was Feb 2000 with a return of +64.7%, while the worst month was Aug 1998 at -24.5%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 4 months.
On a daily basis, HQL closed higher 49% of trading days. The best single day was Feb 17, 2000 with a return of +20.1%, while the worst single day was Apr 14, 2000 at -13.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.07% | 1.43% | -2.28% | 7.56% | 5.40% | 2.69% | 16.62% | ||||||
| 2025 | 8.31% | -2.20% | -5.58% | 1.10% | -1.21% | 4.66% | 2.50% | 9.52% | 11.18% | 14.44% | 2.60% | -5.04% | 45.48% |
| 2024 | 1.93% | 2.62% | -0.44% | -4.04% | 5.44% | 6.38% | 8.47% | 1.62% | -0.33% | -3.45% | 1.49% | -7.99% | 11.03% |
| 2023 | 5.14% | -4.36% | -0.21% | -0.00% | -2.34% | 1.88% | -0.66% | -0.91% | -4.15% | -7.06% | 5.71% | 12.64% | 4.23% |
| 2022 | -5.62% | -7.06% | 0.43% | -6.35% | -3.63% | -2.33% | 4.85% | -1.25% | -5.40% | 7.25% | 5.11% | -5.77% | -19.21% |
| 2021 | 2.78% | 4.98% | -5.65% | 4.01% | -0.76% | 7.58% | -2.99% | 7.08% | -4.81% | 2.26% | -4.77% | -3.07% | 5.52% |
Benchmark Metrics
Tekla Life Sciences Investors has an annualized alpha of 3.62%, beta of 0.80, and R2 of 0.30 versus S&P 500 Index. Calculated based on daily prices since May 04, 1992.
- This stock participated in 94.73% of S&P 500 Index downside but only 93.36% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.30 means the benchmark explains less than half of this stock's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 3.62%
- Beta
- 0.80
- R²
- 0.30
- Upside Capture
- 93.36%
- Downside Capture
- 94.73%
Return for Risk
Risk / Return Rank
HQL ranks 95 for risk / return — in the top 95% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Tekla Life Sciences Investors (HQL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HQL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.00 | ||
| Sortino ratioReturn per unit of downside risk | +1.19 | ||
| Omega ratioGain probability vs. loss probability | 1.49 | 1.37 | +0.12 |
| Calmar ratioReturn relative to maximum drawdown | 6.40 | 2.78 | +3.61 |
| Martin ratioReturn relative to average drawdown | 20.42 | 12.44 | +7.98 |
Dividends
Dividend History
Tekla Life Sciences Investors provided a 11.12% dividend yield over the last twelve months, with an annual payout of $2.04 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $2.04 | $1.82 | $1.86 | $1.27 | $1.36 | $1.69 | $1.56 | $1.40 | $1.62 | $1.62 | $2.07 | $2.80 |
Dividend yield | 11.12% | 10.85% | 14.18% | 9.44% | 9.57% | 8.79% | 7.90% | 8.03% | 10.72% | 8.25% | 12.18% | 11.84% |
Monthly Dividends
The table displays the monthly dividend distributions for Tekla Life Sciences Investors. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.56 | $0.00 | $0.00 | $0.56 | $0.00 | $1.12 | ||||||
| 2025 | $0.00 | $0.47 | $0.00 | $0.00 | $0.43 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $0.50 | $0.00 | $1.82 |
| 2024 | $0.00 | $0.39 | $0.00 | $0.00 | $0.48 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.50 | $0.00 | $1.86 |
| 2023 | $0.00 | $0.33 | $0.00 | $0.00 | $0.32 | $0.00 | $0.00 | $0.32 | $0.00 | $0.00 | $0.30 | $0.00 | $1.27 |
| 2022 | $0.00 | $0.39 | $0.00 | $0.00 | $0.35 | $0.00 | $0.00 | $0.31 | $0.00 | $0.00 | $0.31 | $0.00 | $1.36 |
| 2021 | $0.00 | $0.43 | $0.00 | $0.00 | $0.41 | $0.00 | $0.00 | $0.43 | $0.00 | $0.00 | $0.42 | $0.00 | $1.69 |
Dividend Yield & Payout
Dividend Yield
Tekla Life Sciences Investors has a dividend yield of 11.12%, which means its dividend payment is significantly above the market average.
Payout Ratio
Tekla Life Sciences Investors has a payout ratio of 26.78%, which is quite average when compared to the overall market. This suggests that Tekla Life Sciences Investors strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Tekla Life Sciences Investors. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Tekla Life Sciences Investors was 62.65%, occurring on Oct 9, 2002. Recovery took 2336 trading sessions.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Dot-com crash2000–2002 | -62.65%Oct 2002 | 2y 7mo | 9y 3mo | 11y 11moFeb 2000 - Jan 2012 |
1994 bear market1994 | -48.41%Dec 1994 | 1y 12mo | 1y 1mo | 3y 1moDec 1992 - Jan 1996 |
1998 bear market1998 | -46.67%Oct 1998 | 2y 4mo | 1y 2mo | 3y 7moMay 1996 - Dec 1999 |
2016 bear market2016 | -45.17%Feb 2016 | 6mo 22d | 4y 9mo | 5y 4moJul 2015 - Nov 2020 |
2023 bear market2023 | -38.86%Oct 2023 | 2y 1mo | 1y 11mo | 4y 19dSep 2021 - Sep 2025 |
Drawdown Indicators
| HQL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.65% | -56.78% | -5.87% |
Max Drawdown (1Y)Largest decline over 1 year | -10.25% | -9.10% | -1.15% |
Max Drawdown (3Y)Largest decline over 3 years | -25.10% | -18.90% | -6.20% |
Max Drawdown (5Y)Largest decline over 5 years | -38.86% | -25.43% | -13.43% |
Max Drawdown (10Y)Largest decline over 10 years | -38.86% | -33.92% | -4.94% |
Current DrawdownCurrent decline from peak | 0.00% | -1.80% | +1.80% |
Average DrawdownAverage peak-to-trough decline | -22.24% | -10.71% | -11.53% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.21% | 2.03% | +1.18% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Tekla Life Sciences Investors over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Tekla Life Sciences Investors is priced in the market compared to other companies in the Asset Management industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for HQL, comparing it with other companies in the Asset Management industry. Currently, HQL has a P/E ratio of 2.9. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for HQL compared to other companies in the Asset Management industry. HQL currently has a PEG ratio of 0.1. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for HQL relative to other companies in the Asset Management industry. Currently, HQL has a P/S ratio of 6.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for HQL in comparison with other companies in the Asset Management industry. Currently, HQL has a P/B value of 1.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with HQL
Add Tekla Life Sciences Investors to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with HQL